Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol

21 Aug 2025

Abstract excerpt

Abstract The Realgar-Indigo Naturalis formula (RIF) is a proprietary Chinese medicine, which is one of the important drugs in the treatment of pediatric acute promyelocytic leukemia (APL). However, the dose of RIF in clinical application is not uniform and the long-term effectiveness and safety of combining RIF with all-trans retinoic acid (ATRA) in a larger population of pediatric APL patients remains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Antioxidant Activity and Oxidative Stress
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40841430
DOI: 10.1038/s41392-025-02353-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocolPMID 40841430Read ↗

[Clinical Effect and Safety of CCLG-ALL 2008 (high risk group) Protocol in the Treatment of Childhood Mixed Phenotype Acute Leukemia].Semantic proximity Read ↗

[Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018)].Semantic proximity Read ↗

Acute promyelocytic leukemia: from highly fatal to highly curableSemantic proximity Read ↗

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceSemantic proximity Read ↗

Traditional Chinese medicine for acute myelocytic leukemia therapy: exploiting epigenetic targetsSemantic proximity Read ↗

Acute promyelocytic leukemia (APL): remaining challenges towards a cure for allSemantic proximity Read ↗

Recent advances in acute promyelocytic leukaemiaSemantic proximity Read ↗

Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - A multi-centric clinical study of GD-2008-ALL protocolSemantic proximity Read ↗

Treatment of Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment StrategiesSemantic proximity Read ↗

A pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from ChinaSemantic proximity Read ↗

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of HematologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.